A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Malignancy|Non-hodgkin Lymphoma|Multiple Myeloma|Breast Cancer|Ovarian Cancer|Soft Tissue Sarcoma|Head and Neck Cancer|DLBCL|Mantle Cell Lymphoma|Follicular Lymphoma|Pancreatic Cancer|CLL|Small Cell Lung Cancer|Squamous Cell Carcinoma of Head and Neck|Triple Negative Breast Cancer
Interventions: DRUG: CYT-0851|DRUG: CYT-0851 in combination with gemcitabine|DRUG: CYT-0851 in combination with capecitabine|DRUG: CYT-0851 in combination with rituximab and bendamustine
Sponsor: Cyteir Therapeutics, Inc.